DexCom, Inc. (ETR:DC4)

DexCom Statistics

Total Valuation

DexCom has a market cap or net worth of EUR 18.52 billion. The enterprise value is 17.88 billion.

Market Cap	18.52B
Enterprise Value	17.88B

Important Dates

The last earnings date was Thursday, October 30, 2025.

Earnings Date	Oct 30, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	390.02M
Shares Outstanding	n/a
Shares Change (YoY)	-1.89%
Shares Change (QoQ)	-0.20%
Owned by Insiders (%)	0.32%
Owned by Institutions (%)	93.89%
Float	387.38M

Valuation Ratios

The trailing PE ratio is 30.16 and the forward PE ratio is 22.62.

PE Ratio	30.16
Forward PE	22.62
PS Ratio	4.81
PB Ratio	7.97
P/TBV Ratio	8.29
P/FCF Ratio	20.47
P/OCF Ratio	15.01
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 19.56, with an EV/FCF ratio of 19.76.

EV / Earnings	29.11
EV / Sales	4.58
EV / EBITDA	19.56
EV / EBIT	26.62
EV / FCF	19.76

Financial Position

The company has a current ratio of 1.56, with a Debt / Equity ratio of 0.94.

Current Ratio	1.56
Quick Ratio	1.35
Debt / Equity	0.94
Debt / EBITDA	2.43
Debt / FCF	2.43
Interest Coverage	40.93

Financial Efficiency

Return on equity (ROE) is 30.63% and return on invested capital (ROIC) is 9.85%.

Return on Equity (ROE)	30.63%
Return on Assets (ROA)	7.02%
Return on Invested Capital (ROIC)	9.85%
Return on Capital Employed (ROCE)	18.68%
Revenue Per Employee	375,503
Profits Per Employee	59,927
Employee Count	10,300
Asset Turnover	0.65
Inventory Turnover	3.06

Taxes

In the past 12 months, DexCom has paid 203.10 million in taxes.

Income Tax	203.10M
Effective Tax Rate	24.85%

Stock Price Statistics

The stock price has decreased by -25.76% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-25.76%
50-Day Moving Average	59.39
200-Day Moving Average	69.44
Relative Strength Index (RSI)	28.97
Average Volume (20 Days)	583

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.97

Income Statement

In the last 12 months, DexCom had revenue of EUR 3.85 billion and earned 614.25 million in profits. Earnings per share was 1.53.

Revenue	3.85B
Gross Profit	2.27B
Operating Income	662.83M
Pretax Income	817.36M
Net Income	614.25M
EBITDA	871.14M
EBIT	662.83M
Earnings Per Share (EPS)	1.53

Balance Sheet

The company has 2.83 billion in cash and 2.20 billion in debt, giving a net cash position of 636.24 million.

Cash & Cash Equivalents	2.83B
Total Debt	2.20B
Net Cash	636.24M
Net Cash Per Share	n/a
Equity (Book Value)	2.32B
Book Value Per Share	5.96
Working Capital	1.61B

Cash Flow

In the last 12 months, operating cash flow was 1.23 billion and capital expenditures -329.16 million, giving a free cash flow of 905.06 million.

Operating Cash Flow	1.23B
Capital Expenditures	-329.16M
Free Cash Flow	905.06M
FCF Per Share	n/a

Margins

Gross margin is 59.01%, with operating and profit margins of 17.22% and 15.96%.

Gross Margin	59.01%
Operating Margin	17.22%
Pretax Margin	21.24%
Profit Margin	15.96%
EBITDA Margin	22.63%
EBIT Margin	17.22%
FCF Margin	23.51%

Dividends & Yields

DexCom does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.89%
Shareholder Yield	1.89%
Earnings Yield	3.32%
FCF Yield	4.89%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on June 13, 2022. It was a forward split with a ratio of 4.

Last Split Date	Jun 13, 2022
Split Type	Forward
Split Ratio	4

Scores

DexCom has an Altman Z-Score of 5.5 and a Piotroski F-Score of 6.

Altman Z-Score	5.5
Piotroski F-Score	6